Oncternal Therapeutics, Inc. financial data

Symbol
ONCT on Nasdaq
Industry
Pharmaceutical Preparations
Location
12230 El Camino Real, Suite 230, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
GTX INC /DE/ (to 6/11/2019), GTX INC/TN (to 1/15/2004)
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 531 % -45.5%
Debt-to-equity 25.7 %
Return On Equity -136 % -79.9%
Return On Assets -108 % -59.9%
Operating Margin -2.04K % +60.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2.96M shares -95%
Common Stock, Shares, Outstanding 2.96M shares -95%
Entity Public Float 18.8M USD -64.3%
Common Stock, Value, Issued 3K USD -94.9%
Weighted Average Number of Shares Outstanding, Basic 2.96M shares +0.82%
Weighted Average Number of Shares Outstanding, Diluted 2.96M shares +0.82%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 1.85M USD +114%
General and Administrative Expense 12.7M USD -1.89%
Operating Income (Loss) -37.7M USD +16.2%
Net Income (Loss) Attributable to Parent -36M USD +16.3%
Earnings Per Share, Basic -12.2 USD/shares +47.9%
Earnings Per Share, Diluted -12.2 USD/shares +47.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 6.38M USD -59.7%
Assets, Current 23.3M USD -53.6%
Operating Lease, Right-of-Use Asset 190K USD -48.1%
Other Assets, Noncurrent 412K USD +24.1%
Assets 23.9M USD -53%
Accounts Payable, Current 1.9M USD -14.4%
Employee-related Liabilities, Current 1.8M USD +46.5%
Accrued Liabilities, Current 5.97M USD +142%
Liabilities, Current 8.06M USD +66.7%
Operating Lease, Liability, Noncurrent 50K USD -77.4%
Liabilities 8.11M USD +45%
Accumulated Other Comprehensive Income (Loss), Net of Tax -3K USD +50%
Retained Earnings (Accumulated Deficit) -215M USD -20.1%
Stockholders' Equity Attributable to Parent 15.8M USD -65.1%
Liabilities and Equity 23.9M USD -53%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.44M USD +32.2%
Net Cash Provided by (Used in) Financing Activities -87K USD -108%
Net Cash Provided by (Used in) Investing Activities 7.22M USD
Common Stock, Shares Authorized 120M shares 0%
Common Stock, Shares, Issued 2.96M shares -95%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -301K USD +98.8%
Deferred Tax Assets, Valuation Allowance 66.6M USD +15%
Operating Lease, Liability 235K USD -35.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -36M USD +16.3%
Lessee, Operating Lease, Liability, to be Paid 250K USD -38.6%
Operating Lease, Liability, Current 185K USD +27.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 150K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One 100K USD -49%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 15K USD -63.4%
Deferred Tax Assets, Operating Loss Carryforwards 30M USD +7.56%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 230M USD +2.95%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 66.6M USD +15%
Share-based Payment Arrangement, Expense 6.68M USD -9.05%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%